Acquired erythropoietic uroporphyria secondary to myelodysplastic syndrome with chromosome 3 alterations: a case report.
Sebastian PodlipnikF GuijarroAndrea CombaliaJ To-FiguerasC BadenasD CostaM RozmanS JorgeP AguileraA GayaPublished in: The British journal of dermatology (2018)
Congenital erythropoietic porphyria is a rare autosomal recessive disease caused by a deficiency of uroporphyrinogen III synthase, owing to mutations in UROS in chromosome 10. Occasionally, patients show a mild, late-onset disease, without germline UROS mutations, associated with haematological malignancies. We report a 65-year-old patient with photosensitivity, overexcretion of porphyrins and thrombocytopenia. Bone marrow analysis gave a diagnosis of myelodysplastic syndrome (MDS) with the presence of a derivative chromosome 3, possibly due to an inversion including 3q21 and 3q26 break points. After allogeneic stem-cell transplantation, complete remission of MDS and uroporphyria was achieved. To our knowledge, this is the first reported case of acquired erythropoietic uroporphyria associated with MDS, with chromosome 3 alterations.
Keyphrases
- stem cell transplantation
- late onset
- bone marrow
- copy number
- high dose
- end stage renal disease
- early onset
- newly diagnosed
- healthcare
- chronic kidney disease
- ejection fraction
- mesenchymal stem cells
- peritoneal dialysis
- case report
- magnetic resonance imaging
- low dose
- prognostic factors
- gene expression
- computed tomography
- patient reported outcomes
- dna repair
- autism spectrum disorder
- intellectual disability
- muscular dystrophy